Taken together, our findings are consistent with a linear model in which high expression of JAM-A influences nuclear β-catenin levels, in turn increasing FOXA1 expression which then promotes HER3 expression in breast cancer settings. This evidence concerns the gene ERBB3 and breast cancer.